Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    17312328 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory Central Nervous System (CNS) Lymphoma
Condition: B-Cell Lymphoma Originating in the CNS
Intervention: Drug: Temozolomide
2 Unknown  Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma
Conditions: Brain and Central Nervous System Tumors;   Lymphoma
Intervention: Biological: rituximab

Indicates status has not been verified in more than two years